Starpharma Holdings Limited (SPL)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today Ľ it's FREE! Already a member? Login now!

General Information
Company Name: Starpharma Holdings Limited
Stock Code: SPL
GICS Sub-Industry: Biotechnology
Market Cap ($M): 140
Equiv. Shares (M): 319

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.470 $ 0.445 $ 0.475 $ 0.440 $ 0.440 555,747 $ 0.030  6.818 %

Current Broker Consensus Recommendation more
Recommendation: Buy (2)
Recommendation Date: 26th Mar 2015
Brokers Surveyed: 1

Company Overview

Business Description:
Starpharma Holdings Limited (SPL) is a biotechnology company that engages in the development of dendrimer products for pharmaceutical, life science and other applications. SPL's underlying technology is built around dendrimers, a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. SPL has three core development programs: VivaGel portfolio, drug delivery, and agrochemicals.

Strategy Analysis:
Starpharma Holdings reported a net loss of $1.83m for the half-year ended 31 December 2012. Revenues from ordinary activities were $1.29m, up 24% from last year. Basic and Diluted EPS was (1.0) cent compared to (2.0) cents last year. The net operating cash outflow was $10.24m compared to an outflow of $3.9m in the pcp. No dividend was declared.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016  F -- -0.5 -- -- -- 0.0 --
2015  F -- -5.8 -- -- -- 0.0 --
2014  A -14.6 -5.2 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Bionomics (BNO) $196 M -- -- -- 61.0390 -- 4.7667 0.00 0.00 0.00
CSL (CSL) $43,058 M 0.0899 0.3357 0.0809 32.0650 24.0067 22.2104 1.31 1.74 1.98
Mesoblast (MSB) $1,174 M -- -- -- -- -- -- 0.00 0.00 0.00
Starpharma (SPL) $140 M -- -- -- -- -- -- 0.00 0.00 0.00
Sirtex Medical (SRX) $1,155 M 0.2906 0.6080 0.2575 49.4673 30.7634 24.4641 0.69 0.94 1.42

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
SPL 3.00 -- 3.81 -- 440.0
Market 0.88 16.6 1.30 2.38 1.59
Sector 0.81 16.7 2.72 1.27 7.80

Name Position Start Date
Dr Jacinth (Jackie) Kincaid Fairley Chief Executive Officer,Executive Director 01 July 2006
Dr Peter J Jenkins Non-Executive Deputy Chairman,Non-Executive Director 13 May 1997
Ms Zita Peach Non-Executive Director 01 October 2011
Mr Peter R Turvey Non-Executive Director 19 March 2012
Mr Richard A Hazelton Non-Executive Director 01 December 2006
Mr Robert Bain Thomas Non-Executive Director,Non-Executive Chairman 04 December 2013

Name Position
Nigel Baade Chief Financial Officer,Company Secretary
A Eglezos VP, Business Development
C P Barrett VP, Business Development
J R Paull VP, Development and Regulatory Affairs
D J Owen VP, Research

Substantial Shareholders
Holding Name
14,406,827 (5.05%) The Dow Chemical Company
41,319,032 (14.49%) Allan Gray Australia Pty Ltd
26,357,951 (9.24%) Acorn Capital Limited
37,069,789 (13.00%) M&G Investment Funds

Calendar of Events
Date Event
15 February 2016 Report (Interim)
12 August 2015 Report (Prelim)
12 August 2015 Report (Annual)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Debt Relief

An educational booklet to help you take control of your debts and look to get back on track.

More details...


Markets melt up

By Michael McCarthy (chief market strategist, CMC Markets) 19/12/2014 | Traders and investors caught short heading into the FOMC scrambled for cover in Europe and the US, in many cases driving indices to their best one day performance for 2015.

Aussie Investors take their foot off the accelerator

By Betty Lam (Sales Trader, CMC Markets) 18/12/2014 | Lead by the Fed-fervour offshore, Australians shares jumped on the Yellen cheer wagon. The material and energy stocks were back in vogue as both sectors gained over 3% in morning trade.

Fed Feeds Frenzy

By Michael McCarthy (chief market strategist, CMC Markets) 18/12/2014 | In spite of a frenzied pre-mortem, a benign statement from the US Federal Reserve‚Äôs Open Market Committee and steadying commodity markets drove investors back into share markets overnight. A calmer, stronger ruble helped offset European growth fears, highlighted in the overnight session by further declines in inflation.

Household brands Woolworths and Telstra Heavy Lifting

By Betty Lam (Sales Trader, CMC Markets) 11/12/2014 | Offshore jitters sent ripples through to Australian stocks. The open saw the local equities take 65 points off the index, catalysed by a mass-exit in energy stocks, yet again.

Steady open as Woodside investors wait on details of possible Wheatstone acquisition

By Ric Spooner (Chief Market Analyst, CMC Markets) 10/12/2014 | Yesterday‚Äôs news on Greek politics and China‚Äôs bond market came at a time when US and European stock markets have extended rallies and pushed valuations higher. This makes those markets vulnerable to downward corrections as profit takers act to avoid missing out.

MYEFO and Lima - December could be nasty.

BR Securities Australia Pty Ltd 2/12/2014 | December 2014 could go down as a nasty moment in Australian finance. MYEFO will reveal a deteriorating budget deficit and the UNFCCC meeting in Lima, Peru will provide the agreement, to be ratified in Paris in 2015, on how much (or little) CO2 is to be allowed into the atmosphere from 2020.


Sponsored Links